Complementation assay for drug screening
July 21, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3817837 Specific binding assay with an enzyme modulator as a labeling substance Methods for protein binding enzyme complementation assays Assay for D-1 antagonistic activity of neuroleptic drugs Process for determining the binding capacity of thyroxin-binding globulin In-vitro methods for identifying compositions which are agonists and antagonists of estrogens Membrane Na+ channel protein and related therapeutic compounds Method for measuring the BZ-1 receptor binding activity in a test sample or test compound Potassium channel modulators Patent #: 5328830 InventorAssigneeApplicationNo. 095267 filed on 07/21/1993US Classes:435/7.6, Involving a modified enzyme (e.g., abzyme, recombinant, chemically altered, etc.)435/7.2, Involving a micro-organism or cell membrane bound antigen or cell membrane bound receptor or cell membrane bound antibody or microbial lysate435/7.8, Involving nonmembrane bound receptor binding or protein binding other than antigen-antibody binding435/7.9, Assay in which an enzyme present is a label436/500, THYROID HORMONE TESTS (E.G., T3, T4, TBG, TSH, ETC.)436/501, BIOSPECIFIC LIGAND BINDING ASSAY436/503, Utilizing isolate of tissue or organ as binding agent436/537Signal modification or steric inhibitionExaminersPrimary: Saunders, DavidAttorney, Agent or FirmForeign Patent References
International ClassesG01N 033/535G01N 033/542 G01N 033/566 AbstractCompounds are evaluated for their binding to naturally occurring receptors, by employing the natural ligand conjugated to an enzyme donor fragment of ଲ-galactosidase for competing with the sample compound for the natural acceptor binding site or in the absence of competition where the sample compound binds to an allosteric site. By adding the enzyme acceptor fragment of the ଲ-galactosidase and substrate, the binding affinity of the sample compound may be evaluated as a measure of agonist or antagonist capability.Field of SearchInvolving a micro-organism or cell membrane bound antigen or cell membrane bound receptor or cell membrane bound antibody or microbial lysateInvolving a modified enzyme (e.g., abzyme, recombinant, chemically altered, etc.) Involving nonmembrane bound receptor binding or protein binding other than antigen-antibody binding Assay in which an enzyme present is a label Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay THYROID HORMONE TESTS (E.G., T3, T4, TBG, TSH, ETC.) BIOSPECIFIC LIGAND BINDING ASSAY Utilizing isolate of tissue or organ as binding agent Signal modification or steric inhibition |
| ||||||||||||||
